Woodhouse N J, Niles N, McDonald D, McCorkell S
Horm Res. 1985;21(1):1-9. doi: 10.1159/000180019.
14 previously infertile patients, 11 with radiologically abnormal fossae, and a mean prolactin level of 761 ng/ml (range 49-4,500 ng/ml) conceived on 19 occasions during bromocriptine treatment. So far, 15 healthy infants have been delivered. Treatment was withdrawn soon after conception and the subsequent prolactin changes compared with those of 44 normal subjects. Prolactin levels returned to pretreatment values in 7, but stayed within our normal range (less than 350 ng/ml) in the 6 remaining patients studied. No patient developed signs or symptoms of tumor enlargement. 2 patients, 1 of them with the largest tumor, have now normal prolactin levels and can be considered as cured. Bromocriptine treatment can restore fertility and be safely withdrawn during pregnancy even in patients presenting with large tumors. Nevertheless, patients should be carefully monitored and treatment with bromocriptine re-introduced if necessary.
14例既往不孕患者，其中11例放射学检查发现盆腔异常，平均催乳素水平为761 ng/ml（范围49 - 4500 ng/ml），在溴隐亭治疗期间受孕19次。迄今为止，已分娩15名健康婴儿。受孕后不久停用治疗，并将随后的催乳素变化与44名正常受试者的变化进行比较。7例患者的催乳素水平恢复到治疗前值，但在其余6例研究患者中，催乳素水平保持在我们的正常范围内（低于350 ng/ml）。没有患者出现肿瘤增大的体征或症状。2例患者，其中1例患有最大的肿瘤，目前催乳素水平正常，可视为治愈。即使是患有大肿瘤的患者，溴隐亭治疗也可恢复生育能力，且在孕期可安全停药。然而，应对患者进行仔细监测，必要时重新使用溴隐亭治疗。
